



Article

Deciphering the Effect of Different Genetic Variants on Hippocampal Subfield Volumes in the General Population

Kevin Kirchner, Linda Garvert, Katharina Wittfeld, Sabine Ameling, Robin Bülow, Henriette Meyer zu Schwabedissen, Matthias Nauck, Henry Völzke, Hans J. Grabe and Sandra Van der Auwera

Special Issue

Molecular Research on Depression

Edited by

Dr. Magdalena Sowa-Kućma and Dr. Katarzyna Stachowicz





Article

Deciphering the Effect of Different Genetic Variants on Hippocampal Subfield Volumes in the General Population

Kevin Kirchner ¹, Linda Garvert ¹, Katharina Wittfeld ^{1,2}, Sabine Ameling ^{3,4} , Robin Bülow ⁵ ,
Henriette Meyer zu Schwabedissen ⁶ , Matthias Nauck ^{4,7}, Henry Völzke ^{4,8}, Hans J. Grabe ^{1,2}
and Sandra Van der Auwera ^{1,2,*}

¹ Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 17475 Greifswald, Germany

² German Centre for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17475 Greifswald, Germany

³ Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, 17475 Greifswald, Germany

⁴ German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, 17475 Greifswald, Germany

⁵ Institute for Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, 17475 Greifswald, Germany

⁶ Department Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland

⁷ Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, 17475 Greifswald, Germany

⁸ Institute for Community Medicine, University Medicine Greifswald, 17475 Greifswald, Germany

* Correspondence: auweras@uni-greifswald.de

Abstract: The aim of this study was to disentangle the effects of various genetic factors on hippocampal subfield volumes using three different approaches: a biologically driven candidate gene approach, a hypothesis-free GWAS approach, and a polygenic approach, where AD risk alleles are combined with a polygenic risk score (PRS). The impact of these genetic factors was investigated in a large dementia-free general population cohort from the Study of Health in Pomerania (SHIP, $n = 1806$). Analyses were performed using linear regression models adjusted for biological and environmental risk factors. Hippocampus subfield volume alterations were found for *APOE* $\epsilon 4$, *BDNF* Val, and *5-HTTLPR* L allele carriers. In addition, we were able to replicate GWAS findings, especially for rs17178139 (*MSRB3*), rs1861979 (*DPP4*), rs7873551 (*ASTN2*), and rs572246240 (*MAST4*). Interaction analyses between the significant SNPs as well as the PRS for AD revealed no significant results. Our results confirm that hippocampal volume reductions are influenced by genetic variation, and that different variants reveal different association patterns that can be linked to biological processes in neurodegeneration. Thus, this study underlines the importance of specific genetic analyses in the quest for acquiring deeper insights into the biology of hippocampal volume loss, memory impairment, depression, and neurodegenerative diseases.

Keywords: hippocampal subfields; verbal memory; *APOE*; *BDNF*; *5-HTTLPR*; polygenic score; general population; trisynaptic circuit; candidate genes; depression



Citation: Kirchner, K.; Garvert, L.; Wittfeld, K.; Ameling, S.; Bülow, R.; Meyer zu Schwabedissen, H.; Nauck, M.; Völzke, H.; Grabe, H.J.; Van der Auwera, S. Deciphering the Effect of Different Genetic Variants on Hippocampal Subfield Volumes in the General Population. *Int. J. Mol. Sci.* **2023**, *24*, 1120. <https://doi.org/10.3390/ijms24021120>

Academic Editors: Katarzyna Stachowicz and Magdalena Sowa-Kućma

Received: 19 December 2022

Revised: 2 January 2023

Accepted: 3 January 2023

Published: 6 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The hippocampus is a functional and cytoarchitectural heterogeneous subcortical brain structure within the limbic system [1], and plays an important role in the execution of various brain functions, including episodic memory, learning, and spatial navigation [2,3]. Regarding cytoarchitecture, the hippocampus comprises diverse subfields, which are divided into the cornu ammonis (CA1, CA2/CA3, CA4); presubiculum, subiculum, and parasubiculum; dentate gyrus (granule and molecular layer); hippocampal fissure, fimbria, and tail; as well as the hippocampus–amygdala transition area (HATA) [1,4,5]. It has been widely shown that a loss of hippocampal volume [6,7] and bilateral hippocampal connectivity [8] is associated with the development of mild cognitive impairment (MCI)

and Alzheimer's disease (AD). Thereby, preliminary results emphasized that the specific subfields are more sensitive in predicting AD than the whole hippocampus [9]. Furthermore, alterations in hippocampal volume have been found throughout various psychiatric conditions, including depression and schizophrenia [10].

In addition to functionality and cytoarchitecture differences, several studies also indicated differences in the genetic structure of hippocampal subfield volumes [1,11]. A first review on the genetic influence of single-nucleotide polymorphisms (SNPs) on hippocampal subfields is provided by Vilor-Tejedor and colleagues [1]. The authors explicitly differentiate between genetic variants identified in biologically driven candidate gene approaches and those from hypothesis-free genome-wide association studies (GWAS). On the candidate gene side, their review includes prominent memory-associated variants, such as apolipoprotein E ϵ 4 (*APOE* ϵ 4), brain-derived neurotrophic factor Val⁶⁶Met polymorphism (*BDNF*, rs6265), serotonin-transporter-linked promoter region (5-*HTTLPR*), kidney and brain expressed protein (*KIBRA*, rs17070145), as well as catechol-o-methyltransferase Val¹⁵⁸Met polymorphism (*COMT*, rs4680).

Previous studies discussed the *APOE* ϵ 4 status predominantly in the context of AD and related amyloid β ($A\beta$) deposits, particularly $A\beta$ oligomers, as well as atrophies in the hippocampus [12]. Other studies linked the ϵ 4 allele to cognition and brain structural endophenotypes, especially in late life depression [13–15]. It was also shown that $A\beta$ oligomers exert a toxic influence on synaptic transmission by affecting synaptic long-term potentiation, as well as long-term depression, and might promote synapse loss in the hippocampus [15]. However, recent studies suggest that this effect might be compensated by the presence of one *BDNF*^{Met} allele [16,17], but results on this remain controversial.

BDNF itself is a neuronal growth factor that plays an important role in the induction of neuronal sprouting and differentiation, and is highly expressed in the hippocampus [18,19]. Especially, the single-nucleotide polymorphism *BDNF* Val⁶⁶Met, which causes a valine (Val) to methionine (Met) substitution at codon 66 of the *BDNF* protein, is of high interest because of its known influence on hippocampal functions [16]. It has also been associated with AD and depression in the past [20,21]. Studies in rodents and humans suggested that carriers of the *BDNF*^{Met} allele show lower hippocampal volumes [19,22]. The differential expression of *BDNF* in different hippocampal regions might also suggest a distinct impact of the Val⁶⁶Met polymorphism on hippocampal subfield volumes [16]. Despite these results, a joint analysis of the relation between Val⁶⁶Met and hippocampal volumes in healthy subjects revealed no significant effect [19], and a further meta-analysis of neuropsychiatric patients showed no genotype-dependent effects [23].

Another candidate gene that might influence hippocampal volume is *KIBRA* (also known as the *WWC1* gene), which is generally connected to human memory performance [24–26]. As *KIBRA* interacts with synaptic proteins and is expressed in learning- and memory-related brain regions, such as the hippocampus, a link between *KIBRA* and memory performance seems plausible [25]. In addition, *KIBRA* also appears to be involved in depression-associated cognitive alterations [27]. Differences in hippocampal activation during memory retrieval were observed for *KIBRA* (rs17070145) T allele carriers, which show an increased episodic memory performance compared to non-carriers [24,28]. Other studies also observed larger hippocampal volumes for T allele carriers than for non-carriers [29,30]. Furthermore, *KIBRA* might modulate the association between hippocampal structure and episodic memory performance in combination with the gene *COMT* [31].

The *COMT* gene is located on chromosome 22 and is highly expressed in the hippocampus. Especially, the Val¹⁵⁸Met polymorphism is of particular interest and plays an important role in dopamine metabolism [32] and the modulation of different brain functions [33]. The amino acid substitution of valine (Val) to methionine (Met) at codon 158 leads to a three- to fourfold reduction in enzymatic activity, which causes increased dopamine levels. Since balanced dopamine neurotransmission is necessary for the optimal regulation of human cognition, mood, and behavior, the *COMT*^{Val} allele has often been associated with poorer cognitive performance in healthy individuals [34] as well as in de-

pressed subjects [35]. However, little is known about the impact of *COMT* on hippocampal subfield volumes. So far, studies suggest that healthy *COMT*^{Val} carriers exhibit smaller hippocampal volumes than *COMT*^{Met} carriers [36–38]. Hayes and colleagues [32] reported similar results for individuals with severe PTSD symptomatology.

The 5-HTTLPR variation in the serotonin transporter gene *SLC6A4* is another prominent genetic variant, which regulates the availability of serotonin within the synaptic gap [39]. Serotonin (5-hydroxytryptamine, 5-HT) has substantial regulatory effects regarding neurite outgrowth, synaptogenesis, cell survival, and brain development. The S allele of 5-HTTLPR is known to be associated with diminished 5-HT transporter and, consequently, 5-HT function [40]. Previous studies also reported negative effects of the 5-HTTLPR S allele on hippocampal volumes, particularly for S allele carriers with MDD [40–44]. Nonetheless, again, these results are controversial [45].

However, despite plausible biological explanations for the effects of these genetic variants on hippocampal volumes, the results presented in the review by Vilor-Tejedor and colleagues [1] remain inconclusive due to the heterogeneity of samples and restricted sample sizes.

In a hypothesis-free GWAS approach, van der Meer and colleagues were able to identify 18 genome-wide significant SNPs spanning 15 loci associated either with whole hippocampal volume or specific hippocampal subfields. The genes mapped to these SNPs are involved in biological processes related to neuronal differentiation, locomotor behavior, schizophrenia, and AD [11].

The current study aimed to disentangle the effects of various genetic factors on specific hippocampal subfield volumes in a large dementia-free general population sample. The genetic factors stem from three different sources: (1) a biologically driven candidate gene approach, (2) a hypothesis-free GWAS approach, and (3) a polygenic approach, where AD risk alleles are combined with a polygenic risk score (PRS). In addition to direct effects, interaction effects between significant variants were investigated, as previous results also show moderation effects between genetic variants. In the final step, we also performed association analyses between hippocampal subfield volumes and memory performance in our sample.

2. Results

2.1. Sample Characteristic

The final sample for the calculation of direct effects between genetic variants and hippocampal subfield volumes consisted of 1806 subjects (53% females). Comparing males and females, differences in education, depression measures, verbal memory, as well as brain measures were observed (Table 1). The distribution of genetic factors was similar between both sexes (see Table 1, Supplementary Table S1). All SNPs were in Hardy-Weinberg equilibrium (HWE $p > 0.001$). A sample missingness flowchart is provided in the Supplementary Materials (see Supplementary Figure S1). A full list of GWAS SNPs can be found in the Supplementary Materials as well as a sample characteristic including all hippocampal subfields (Tables S1 and S2).

In Figure 1, the correlation matrix for total hippocampal volume and its subfields is displayed. Highest correlations with total hippocampal volume were observed for molecular layer dentate gyrus, granule layer dentate gyrus, as well as for the CA1 and CA4 subfields (all $r > 0.9$), the lowest correlation was for fissure ($r = 0.25$). The lowest absolute correlation was observed between fissure and HATA with $r = -0.01$. The strongest negative correlation was observed between fissure and fimbria ($r = -0.19$).

Table 1. Sample characteristics (n = 1806) for the investigated TREND-0 sample.

	Females (n = 955)	Males (n = 851)	Comparison
Age	50.6 (13.5), [21–81]	50.4 (14.3), [21–81]	$T = -0.23, p = 0.82$
Education			
<10 years	139 (14.6%)	115 (13.5%)	$\chi^2 = 23.5, p < 0.001$
=10 years	567 (59.4%)	425 (49.9%)	
>10 years	249 (26.0%)	311 (36.6%)	
Hippocampal volume in cm ³	6.6 (0.57), [4.5–8.3]	7.2 (0.67), [5.0–9.7]	$T = 20.7, p < 0.001$
ICV in cm ³	1496 (116), [1054–1914]	1693 (131), [1314–2135]	$T = 33.8, p < 0.001$
MDD lifetime (yes)	219 (22.9%)	106 (12.5%)	$\chi^2 = 33.9, p < 0.001$
Missing	8 (0.8%)	4 (0.5%)	
PHQ-9 sum score	4.3 (3.68), [0–25]	3.2 (3.36), [0–26]	$T = -6.2, p < 0.001$
Missing	66 (6.9%)	53 (6.2%)	
Immediate verbal memory score	5.54 (1.26), [0–8]	5.25 (1.22), [0–8]	$T = -5.07, p < 0.001$
Delayed verbal memory score	6.03 (1.59), [−3–8]	5.51 (1.68), [−1, 8]	$T = -6.82, p < 0.001$
Missing	6 (0.6%)	9 (1.1%)	
APOE $\epsilon 4$ status			$\chi^2 = 0.48, p = 0.49$
$\epsilon 4$ allele carrier	217 (22.7%)	204 (24.0%)	
missing	22 (2.3%)	24 (2.8%)	
5-HTTLPR			$\chi^2 = 1.99, p = 0.37$
SS	202 (21.2%)	159 (18.7%)	
SL	439 (46.0%)	395 (46.4%)	
LL	224 (23.5%)	215 (25.3%)	
Missing	90 (9.4%)	82 (9.6%)	
COMT Val158Met			$\chi^2 = 2.83, p = 0.24$
GG (Val/Val)	254 (26.6%)	252 (29.6%)	
GA (Val/Met)	505 (52.9%)	418 (49.1%)	
AA (Met/Met)	196 (20.5%)	181 (21.3%)	
BDNF Val66Met			$\chi^2 = 3.68, p = 0.16$
AA (Met/Met)	36 (3.8%)	41 (4.8%)	
GA (Val/Met)	274 (28.7%)	270 (31.7%)	
GG (Val/Val)	645 (67.5%)	540 (63.5%)	
KIBRA rs17070145			$\chi^2 = 0.60, p = 0.74$
TT	105 (11.0%)	92 (10.8%)	
CT	416 (43.6%)	357 (42.0%)	
CC	434 (45.4%)	402 (47.2%)	

Full sample characteristics for the main analyses on the association between genetic variants and hippocampal subfields. Metric variables are displayed as mean (standard deviation) and range, categorical variables as count/number (percentage). ICV, intracranial volume; MDD, major depressive disorder; PHQ-9, Patient Health Questionnaire. The t -tests and χ^2 tests were calculated on non-missing data.

2.2. Direct Effects of Candidate Variants on Hippocampal Subfields

2.2.1. APOE $\epsilon 4$

The APOE $\epsilon 4$ allele revealed negative effects on whole hippocampal volume ($p = 0.01$) as well as on different subfields (CA1, $p = 0.003$; molecular layer DG, $p = 0.014$; granule layer dentate gyrus, $p = 0.028$; HATA, $p = 0.033$; and hippocampus tail, $p = 0.046$; Table 2). As can be seen in Figure 1, this fits with the high correlations between whole hippocampal volume, CA1 region, molecular layer, and granule layer ($r > 0.9$).




Figure 1. Pearson correlation heatmap of the total hippocampal volume and its subfields in TREND-0 (both hemispheres combined). CA, cornu ammonis; DG, dentate gyrus; HATA, hippocampus–amygdala transition area.

Table 2. Association results for the direct effects of candidate genetic variants and polygenic risk score for Alzheimer’s disease (PRS AD) on hippocampal volume and its subfield volumes in TREND-0 (n = 1806).

HC Volume	<i>APOE</i>	<i>5-HTTLPR</i>	<i>BDNF</i>	<i>COMT</i>	<i>KIBRA</i>	PRS AD
Whole HC	0.010 (–)	0.017 (–)	0.038 (–)	0.180 (–)	0.370 (–)	0.564 (–)
CA1	0.003 (–)	0.032 (–)	0.310 (–)	0.200 (–)	0.540 (–)	0.450 (–)
CA3	0.110 (–)	0.026 (–)	0.640 (+)	0.440 (–)	0.680 (+)	0.346 (+)
CA4	0.071 (–)	0.034 (–)	0.210 (–)	0.410 (–)	0.390 (–)	0.800 (+)
Presubiculum	0.450 (–)	0.740 (–)	0.014 (–)	0.480 (–)	0.580 (–)	0.208 (–)
Subiculum	0.190 (–)	0.400 (–)	0.025 (–)	0.500 (–)	0.230 (–)	0.347 (–)
Parasubiculum	0.770 (+)	0.740 (+)	0.170 (–)	0.910 (–)	0.560 (–)	0.742 (+)
Molecular layer DG	0.014 (–)	0.019 (–)	0.084 (–)	0.210 (–)	0.500 (–)	0.555 (–)
Granule layer DG	0.028 (–)	0.020 (–)	0.140 (–)	0.320 (–)	0.500 (–)	0.911 (–)
HC tail	0.046 (–)	0.009 (–)	0.032 (–)	0.210 (–)	0.170 (–)	0.926 (–)
Fimbria	0.350 (–)	0.670 (–)	0.910 (–)	0.960 (+)	0.180 (+)	0.327 (–)
Fissure	0.790 (+)	0.810 (+)	0.400 (+)	0.580 (+)	0.520 (–)	0.351 (+)
HATA	0.033 (–)	0.510 (–)	0.840 (–)	0.500 (–)	0.640 (+)	0.539 (–)

The *p*-values and effect directions (in brackets; positive + and negative –) are presented, significant results are displayed in bold. Analyses were adjusted for age, sex, intracranial volume, educational attainment, three genetic PCs, and genetic batch. Coding alleles: *5-HTTLPR* = L allele, *APOE* = ε4 allele, *BDNF* = Val allele, *COMT* = Met allele, *KIBRA* = C allele. HC, hippocampus; CA, cornu ammonis; DG, dentate gyrus; HATA, hippocampus–amygdala transition area.

2.2.2. 5-HTTLPR

The serotonin transporter variant revealed comparable results regarding its effects on hippocampal subfields as *APOE* ϵ 4. The L allele was associated with a reduced whole hippocampal volume ($p = 0.017$), with negative effects on CA1 ($p = 0.032$), molecular layer DG ($p = 0.019$), granule layer DG ($p = 0.020$), and hippocampal tail ($p = 0.009$) (see Table 2).

2.2.3. BDNF

For *BDNF* Val⁶⁶Met polymorphism, the association pattern was largely different from those for *APOE* ϵ 4 and 5-HTTLPR. The Val allele was associated with reduced whole hippocampal volume ($p = 0.038$), which could especially be attributed to reductions in the presubiculum ($p = 0.014$) and subiculum ($p = 0.025$) subfield, as well as the hippocampal tail ($p = 0.032$; Table 2).

2.2.4. COMT

No significant results were observed.

2.2.5. KIBRA

No significant results were observed.

Additional adjustment for MDD did not change the significance of the results. A graphical representation of the significant associations between candidate genetic factors and the hippocampal subfield volumes can be found in Figure 2.




Figure 2. Graphical representation of all nominal significant associations between the investigated genetic candidate variants and hippocampal subfield volumes (for *COMT* and *KIBRA*, no significant association were observed). Coding alleles: 5-HTTLPR = L allele, *APOE* = ϵ 4 allele, *BDNF* = Val allele. CA, cornu ammonis; DG, dentate gyrus; HATA, hippocampus–amygdala transition area; HC, hippocampus.

2.3. Direct Effects of GWAS SNPs on Hippocampal Subfields

We used the 17 available genome-wide significant GWAS lead SNPs from van der Meer and colleagues [11] to look for direct effects on hippocampal subfield volumes in our sample, and to compare our results with the findings from the original publication. In TREND-0, we were able to replicate significant associations on whole hippocampal volume for four out of seven available lead SNPs from the GWAS (rs17178139, rs1861979, rs57246240, rs7873551; see Table 3 for an overview and Supplementary Table S3). From the effects on hippocampal subfields, only the effect of rs160459 on granule layer DG, of rs17178006 on CA1, and of rs2909443 on hippocampal tail could be replicated at a nominal significant level and pointing to the same effect alleles.

Table 3. Comparison of significant GWAS hits with nominal significant associations in TREND-0 (n = 1806).

Lead SNP (Effect Allele)	Mapped Genes	Sig. Subfields GWAS	Sig. Subfields TREND-0
rs12218858 (C)	<i>FAM175B, FAM53B, METTL10</i>	Whole HC (+)	HC tail (+)
rs1419859 (C)	<i>PARP11</i>	Whole HC (+)	Subiculum (−)
rs17178139 (G)	<i>MSRB3</i>	Whole HC (+)	Whole HC, CA1, CA3, CA4, Molecular layer DG, Granule layer DG (all +)
rs160459 (A)	<i>DACT1</i>	CA1 (−), Granule layer DG (−), HC tail (+)	CA3, CA4, Granule layer DG (all −)
rs6675690 (T)	/	HC tail (−)	None
rs10888696 (G)	<i>DMRTA2, FAF1, CDKN2C</i>	HC tail (−)	CA1, CA3, Fissure (all −)
rs1861979 (T)	<i>DPP4</i>	Whole HC (+)	Whole HC, CA4, Granule layer DG, HC tail (all +)
rs7630893 (C)	<i>ATP1B3, TFDP2</i>	Whole HC (+)	Fimbria (−)
rs57246240 (G)	<i>MAST4</i>	Whole HC (−)	Whole HC, CA1, CA3, CA4, Presubiculum, Subiculum, Molecular layer DG, Granule layer DG, HC tail, Fissure (all −)
rs13188633 (C)	/	HC tail (+)	CA3, HATA (all −)
rs10474356 (A)	/	HC tail (+)	None
rs55736786 (C)	<i>FAM172A, POU5F2</i>	HC tail (+)	None
rs9399619 (G)	<i>SAMD5</i>	Subiculum (+)	None
rs7873551 (T)	<i>ASTN2</i>	Whole HC (+)	Whole HC, CA1, CA4, Subiculum, Molecular layer DG, Granule layer DG, HC tail, HATA (all +)
rs4962694 (G)	<i>FAM175B, FAM53B, METTL10</i>	Molecular layer DG (−)	HC tail (+)
rs17178006 (T)	<i>WIF1, LEMD3, MSRB3</i>	CA1 (+), Presubiculum (−)	Whole HC, CA1, Molecular layer DG, HC tail (all +)
rs2909443 (G)	<i>SLC4A10, DPP4</i>	HC tail (+)	Whole HC, CA4, Granule layer DG, HC tail (all +)

Effect directions (in brackets) are presented. Analyses were adjusted for age, sex, intracranial volume, educational attainment, three genetic principal components, and genetic batch. HC, hippocampus; CA, cornu ammonis; DG, dentate gyrus; HATA, hippocampus–amygdala transition area. rs77956314 is not available in our dataset. “/” = unknown gene.

2.4. Association between the PRS for AD and Hippocampal Subfield Volumes

The PRS for AD exhibited no significant effect on any of the hippocampal subfield volumes (all $p > 0.05$).

2.5. Interaction Analyses between Significant Genetic Factors

Interaction effects were tested for genetic factors that exhibited a significant direct effect on hippocampal volumes. If two variants revealed significant direct effects on the same subfield, their interaction effect was tested on the same subfield. For candidate SNPs, direct effects in TREND-0 were relevant; for GWAS SNPs, we selected only those SNPs whose effect on hippocampal subfield volumes could be replicated in TREND-0. This resulted in 28 interactions that were tested (see Supplementary Table S4). None of the interactions revealed a significant effect on the respective hippocampal subfield.

2.6. Association between Memory Performance and Hippocampal Subfields

No significant associations between verbal memory performance and hippocampal subfields were observed in the total sample. Stratified by median age (50 years), significant associations between the delayed verbal memory score and hippocampal subfields were observed only in older subjects. Volumes of the whole hippocampus and the subfields of CA1, CA4, molecular layer DG, and granule layer DG were positively associated with a higher delayed verbal memory score. For a detailed overview, see Table 4.

Table 4. Association results between the verbal memory scores and hippocampal subfield volumes in TREND-0 (n = 1806).

Volume	Short-Term Retrieval	Long-Term Retrieval	Long-Term Retrieval (Young)	Long-Term Retrieval (Old)
Whole HC	0.550 (+)	0.100 (+)	0.740 (–)	0.017 (+)
CA1	0.930 (+)	0.160 (+)	0.540 (–)	0.015 (+)
CA3	0.320 (+)	0.210 (+)	0.940 (+)	0.120 (+)
CA4	0.340 (+)	0.071 (+)	10.000 (+)	0.027 (+)
Presubiculum	0.650 (+)	0.120 (+)	0.550 (+)	0.100 (+)
Subiculum	0.620 (+)	0.170 (+)	0.400 (–)	0.018 (+)
Parasubiculum	0.660 (+)	0.350 (+)	0.510 (+)	0.430 (+)
Molecular layer DG	0.690 (+)	0.080 (+)	0.710 (+)	0.009 (+)
Granule layer DG	0.360 (+)	0.060 (+)	0.980 (–)	0.019 (+)
HC tail	0.980 (+)	0.970 (+)	0.760 (–)	0.760 (+)
Fimbria	0.490 (+)	0.330 (+)	0.610 (+)	0.310 (+)
Fissure	0.330 (–)	0.530 (+)	0.510 (–)	0.280 (+)
HATA	0.350 (+)	0.870 (+)	0.410 (–)	0.310 (+)

The *p*-values and effect directions (in brackets, positive +, negative –) are presented, significant results are displayed in bold. Analyses were adjusted for age, sex, intracranial volume, educational attainment, and PHQ-9 sum score. HC, hippocampus; CA, cornu ammonis; DG, dentate gyrus; HATA, hippocampus–amygdala transition area. The sample was separated by median split (median = 50 years).

3. Discussion

Our results reveal that genetic candidate variants selected from various biological systems show different association patterns in hippocampal subfield volumes. Hippocampal subfield volume alterations were found for *APOE* ϵ 4, *BDNF*^{Val}, and *5-HTTLPR* L allele carriers. We could also replicate part of the results from a large hippocampus subfield GWAS [11]. Interaction analyses between the significant SNPs and combining SNPs to a PRS for AD revealed no significant results. Moreover, our results confirm that hippocampal volume reductions are influenced by genetic variation, and have an impact on memory performance, especially in older age groups [46].

In order to integrate our findings into the current state of research, we searched for pathways and biological processes involving the genetic candidate variants that might influence hippocampal subfield volumes, and searched for explanations regarding how this might finally influence memory performance. As previous studies suggest, *APOE* [47], *BDNF* [48], and *5-HTTLPR* [49] might be important factors in neuroplasticity and neurodegeneration. While neuroplasticity is generally understood as the ability of neural brain networks to change through development and rearrangement [50], neurodegeneration describes the loss of neurons and synapses [47].

For *APOE* ϵ 4 carriers, our results show reduced hippocampal volumes, especially for the dentate gyrus (granule and molecular layer) and the CA1, which play important roles in the trisynaptic circuit that represents a prominent pathway involved in information processing. It comprises different areas, such as the entorhinal cortex as well as the

hippocampal subfields dentate gyrus, CA1, and CA3 [51]. It is widely assumed that sensory information initially reaches the entorhinal cortex, enters the hippocampus via the DG, and is then forwarded to CA3 and CA1 for memory consolidation [5]. To date, researchers also assume that the neuropathology of AD initially appears in the transentorhinal cortex and subsequently spreads into the entorhinal cortex and hippocampus [52]. Thus, our results are in line with the observation that *APOE* ϵ 4 carriers are especially affected in developing AD [12]. However, how *APOE* ϵ 4 impacts neuronal loss is still debated. Studies on AD suggest that A β plaques might be a common factor in the etiology of neurodegeneration in *APOE* ϵ 4 carriers [47,53]. Here, the soluble A β oligomers especially appear to exert a toxic influence on synaptic transmission, and might promote neurodegenerative processes in the hippocampus [54,55]. Among others, the binding of extracellular A β oligomers might lead to a functional disruption of different receptor types, which results in synaptic dysfunction and neurodegeneration. Furthermore, the possible insertion of A β oligomers into the cell membrane and their formation of ion channels might promote neurodegenerative processes [54].

In contrast to *APOE* ϵ 4, our observation of decreased hippocampal subfield volumes in *BDNF*^{Val} carriers initially appears counterintuitive. To date, the Met allele has been identified to decrease the activity-dependent secretion of *BDNF* due to an interference with the intracellular trafficking [56], and was associated with reduced *BDNF* levels, smaller hippocampal volumes, as well as impaired cognitive function [57]. Thus, we assumed that there were decreased hippocampal subfield volumes for Met allele carriers. Nevertheless, inconsistent findings about *BDNF* Val⁶⁶Met are not uncommon, and might be attributable to factors such as age, sex, ethnicity, environmental factors, genetic modeling, gene–gene interactions, and non-linear genetic effects [48]. The *BDNF* precursor pro*BDNF* was found to be able to induce cell apoptosis in cultured neurons [58], AD cases [59], and post-stroke depression cases [60] through the interaction with the P75^{NTR} receptor and its co-receptor sortilin; however, it still remains unclear whether pro*BDNF*^{Val} carriers are at higher risk than pro*BDNF*^{Met} carriers, making more research on this topic necessary. Nevertheless, our observed volume reductions for the subiculum, presubiculum, and hippocampus tail might substantiate these observations.

In addition, connections between *BDNF* and the serotonin transporter (5-HTTLPR) have also been discussed in the context of hippocampal neurogenesis and neurodegeneration [49]. Regions of high 5-HTTLPR concentrations are, among others, the hippocampal molecular layer and CA3 [61]. As previous studies suggest, 5-HTTLPR activity and *BDNF* levels are able to regulate each other through reciprocal feedback loops and enhance the growth and survival of neurons [62,63]. For instance, high levels of *BDNF* release result in the stimulation of 5-HTTLPR activity, which increases 5-HT clearance. As a consequence, the 5-HT receptor activity and activation of CREB (cAMP response element-binding protein) become reduced, which, in turn, leads to decreased *BDNF* expression. Vice versa, lower *BDNF* levels downregulate 5-HTTLPR activity and increase the expression of *BDNF* [63] via enhanced 5-HT receptor activity and activation of CREB. Since *BDNF* acts as a factor for neurogenesis and is associated with the growth, differentiation, and survival of neurons [64], disturbances of the homeostatic equilibrium of 5-HTTLPR and *BDNF* might explain hippocampal volume alterations [63]. One proposal for how this homeostasis might be impaired is provided by Haase and Brown [63]. They refer to inflammatory processes driven by infections or stressors, and describe the cytokine-induced upregulation of 5-HTTLPR activity, which leads to the depletion of *BDNF* levels and alterations in neuroplasticity. If so, the effect should be especially strong for 5-HTTLPR L allele carriers. This idea is supported by the observations that the intake of selective serotonin reuptake inhibitors (SSRIs) is associated with hippocampal neurogenesis (including increased volumes, cell proliferation, and synaptic plasticity) [64], and proves to be particularly effective for L allele carriers [65,66]. By blocking 5-HTTLPR, SSRIs intervene in the mentioned homeostatic equilibrium and, thus, facilitate the expression of *BDNF* [63].

In our study, neither *COMT* nor *KIBRA* genetic variants revealed a significant effect on hippocampal subfield volumes. Reasons for this might be limited power due to a restricted sample size and small effect sizes of SNPs, negligible effects in the population-based sample compared to clinical cohorts, or the cross-sectional design where progressive effects are not captured. Beyond this, structural MRI data for the hippocampus can only reveal neurodegenerative effects due to differences in volume, and effects on structural plasticity and functional differences might be missed.

Concerning the GWAS lead SNPs, we found strong significant associations in our sample, especially for rs17178139 (*MSRB3*), rs1861979 (*DPP4*), rs7873551 (*ASTN2*), and rs572246240 (*MAST4*), which are in line with the recent GWAS as well as a previous meta-analysis by Hibar and colleagues [2] on hippocampus total volume. Moreover, *MSRB3* seems to be involved in processes of cell proliferation [67] and synaptic plasticity [68], *DPP4* might impact the development of oxidative stress and inflammation, which are both associated with the development of depression [69], and *ASTN2* also seems to play a role in synaptic plasticity [70] as well as in neurodevelopmental disorders [71]. Although previous knowledge about *MAST4* is scarce, *MSRB3*, *DPP4*, and *ASTN2* might be of particular interest for further candidate gene approaches.

The attempt to identify interactions between significant genetic variants as well as the application of a PRS for AD revealed no significant results.

Our findings have to be seen in the light of several limitations. Our analyses are performed on SHIP data, which are derived from a highly homogeneous general population sample of mainly European ancestry. Since we had no replication sample available, we cannot generalize our results or make any assertions as to whether our results are transferable to other cohorts and populations. Moreover, the quality of the MRI scans was limited by the resolution of the 1.5 T scanner used in this study. In addition, our conclusions are based on genetic effects and lack support from mechanistic wet lab experiments. Therefore, it is necessary to further investigate the hypothesized biological mechanisms affecting hippocampal subfields in disease samples and animal models.

In sum, our results potentially demonstrate an association between genetic variants and a reduction in certain hippocampal subfield volumes in a population-based cohort. To our knowledge, we are the first to analyze the impact of several different genetic predictors on hippocampal subfield volumes in such a structured manner using one target sample, correcting for several potential covariates, and including complex genetic variants, such as the *APOE* $\epsilon 4$ status or *5-HTTLPR*. We were able to identify association patterns of individual SNPs that can be linked to biological processes in neurodegeneration in a relatively healthy and dementia-free population. Whether these patterns can be transferred to disease populations needs to be clarified in independent disease cohorts. Thus, this study underlines the importance of gene-based analyses in the quest for insights into hippocampal volume loss, memory impairment, and neurodegenerative diseases, and opens the field for generating hypotheses for neurodegenerative diseases.

4. Materials and Methods

4.1. SHIP-TREND Sample

SHIP-TREND is a general population cohort from the Study of Health in Pomerania (SHIP) [72]. From 2008 until 2012, the baseline sample SHIP-TREND-0 (hereafter referred to as TREND-0) was examined with the aim of assessing the prevalence and incidence of common diseases and their risk factors in the general population. All 4420 participants underwent a standardized computer-assisted personal interview, during which they provided information on sociodemographic and lifestyle factors, and also provided different biofluids for OMICS analyses. A subsample of $n = 2047$ participants also underwent whole-body magnetic resonance imaging (MRI).

The investigations in the SHIP study were carried out in accordance with the Declaration of Helsinki, including written informed consent from all participants. The survey

and study methods were approved by the Ethics Committee at the University Medicine Greifswald, Germany.

4.1.1. Verbal Memory

In TREND-0, the word list of the Nuremberg Age Inventory (NAI) was used as a measure for immediate and delayed verbal memory performance. The NAI is a German test developed to measure cognitive abilities during brain aging [73,74]. It includes, among other subtests, a list of eight neutral words that are read to the participant, who is asked to immediately recall as many words as possible (immediate verbal memory score). After 20 min, the participant is asked to retrieve the eight words previously learned from a reading list containing eight additional distractor words. The number of correctly identified words is summarized as the sum score minus the number of wrongly identified distractor words (delayed verbal memory score).

4.1.2. Covariates

In TREND-0, a diagnostic interview for mental disorders was performed based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual for Mental Disorders (IV edition) [75,76], which also includes the diagnosis of lifetime major depressive disorder (MDD). Current depressive symptoms were assessed in TREND-0 using the patient health questionnaire (PHQ-9), a nine-item self-report questionnaire with high reliability and validity [77] where individual symptom load is summed up to a score ranging from 0 to 27. Education, measured as the number of schooling years, was divided into three categories according to the German school system: less than 10 years, exactly 10 years, and more than 10 years.

4.2. Genetic Data

4.2.1. Genome-Wide SNP Chip

Genotyping of a subset of the TREND-0 subjects ($n = 986$) was performed using the Illumina Infinium HumanOmni 2.5 Bead Chip. The remaining TREND-0 sample ($n = 3134$) was genotyped at a later stage using the Illumina Infinium GSA. Imputation of genotypes was performed using the HRCv1.1 reference panel and the Eagle and minimac3 software implemented in the Michigan Imputation Server for pre-phasing and imputation, respectively. For more detail, see Völzke and colleagues [72]. SNPs with a Hardy–Weinberg equilibrium p -value < 0.0001 , a call rate < 0.95 , and a MAF $< 1\%$ were removed before imputation.

4.2.2. APOE $\epsilon 4$ Carrier Status

The APOE (apolipoprotein E) genotypes were determined on the basis of the two single-nucleotide polymorphisms rs429358 (C; T) and rs7412 (T; C) from the resulting imputation (imputation quality > 0.8 ; Hardy–Weinberg equilibrium, $p > 0.05$) [15,78]. As we used the data from the genome-wide SNP chip instead of strand-specific genotyped SNPs for the determination of APOE status, two ambiguous SNP combinations occurred where APOE $\epsilon 2/\epsilon 4$ and $\epsilon 1/\epsilon 3$ could not be discriminated (<http://www.snpedia.com/index.php/APOE>; accessed on 18 October 2022). Those participants were excluded from the genetic analyses ($n = 99$ in the total TREND-0 sample). Subjects were defined as APOE $\epsilon 4$ carriers if they had at least one $\epsilon 4$ allele.

4.2.3. Genotyping of the Serotonin Transporter

The SLC6A4 gene harbors a variable number tandem repeat (VNTR) polymorphism in its transcription control region (5-HTTLPR). Both variants (Short, Long) differ by a 43 bp insertion/deletion (“biallelic” 5-HTTLPR). Within the inserted fragment, an additional common SNP occurs (rs25531). This finding suggested that 5-HTTLPR is triallelic, with S, LA, and LG alleles. We developed a restriction fragment length polymorphism (RFLP) method that allows for the determination of both variants (S/L; rs25531) within one assay.

For further methodological details, see the Supplementary Materials of Van der Auwera and colleagues [57].

Based on previous reports on gene expression, we also classified the genotypes into three functional “triallelic” genotypes: LALA = LL; LGLA or SLA = SL; and LGLG or LGS or SS = SS [58]. As the results for the “biallelic” and “triallelic” versions of the 5-HTTLPR were comparable, we only report results for the triallelic version. The 5-HTTLPR genotype was available for $n = 3345$ subjects in TREND-0.

4.2.4. Polygenic Risk Score for AD

A polygenic risk score (PRS) is a statistical genetic measurement that sums an individual’s risk-increasing alleles weighted by their estimated effect size for a specific phenotype or disease. The PRS employed in this study was calculated using PRS-CS, a method that utilizes a high-dimensional Bayesian regression framework and places a continuous shrinkage (CS) prior on SNP effect sizes using GWAS summary statistics and an external linkage disequilibrium (LD) reference panel [79]. Here, the original effect sizes were taken from a GWAS by Kunkle and colleagues [80] on genetic risk factors for diagnosed AD. The LD reference panel was constructed using a European subsample of the UK Biobank [81]. For the remaining parameters, the default options as implemented in PRS-CS were adopted.

4.3. MRI Data

Subjects from TREND-0 were asked to participate in a whole-body MRI assessment. After exclusion of subjects who refused participation or fulfilled exclusion criteria for MRI (e.g., cardiac pacemaker) 2047 subjects from TREND-0 underwent the MRI scanning procedure and provided data [82]. For structural MRI data, participants were scanned with a 1.5 Tesla MRI (MAGNETOM Avanto; Siemens Healthcare, Erlangen, Germany) with a T1-weighted magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence and the following parameters: axial plane, repetition time = 1900 ms, echo time = 3.4 ms, flip angle = 15° , original resolution = $1.0 \times 1.0 \times 1.0 \text{ mm}^3$, matrix = 256×176 , bandwidth = 130 Hz/Pixel [83]. The brain phenotypes, including total intracranial volume, total hippocampus volume, and hippocampal subfield volumes, were generated using FreeSurfer version 7.1.1 [84]. The subfields comprised the following volumes: cornu ammonis (CA1, CA2/CA3 (referred to as CA3), CA4); presubiculum, subiculum, and parasubiculum; dentate gyrus (granule and molecular layer); hippocampal fissure, fimbria, and tail; as well as hippocampus–amygdala transition area (HATA).

4.4. Statistical Analyses

Subject characteristics were assessed by means, standard deviations and ranges for metric variables and with numbers and percentages for categorical data. Sample comparisons were performed using t -tests for metric variables and χ^2 tests for categorical variables.

4.4.1. Direct Effects of Genetic Markers on Hippocampal Subfields

Ordinary least square (OLS) linear regression models with robust estimates were applied to investigate the association of different genetic variants and the AD PRS with hippocampal subfield volumes. These genetic variants included the following candidate variants: APOE $\epsilon 4$ allele carrier status, the BDNF Val⁶⁶Met polymorphism (rs6265), the COMT Val¹⁵⁸Met polymorphism (rs4680), the triallelic version of the 5-HTTLPR, and the KIBRA polymorphism rs17070145, as well as 17 lead SNPs (rs77956314 not available in our data) spanning 15 loci from a recent GWAS on hippocampal subfield volumes in the UK Biobank [11]. Analyses were adjusted for age, sex, genetic batch, three genetic principal components (PCs), education level, and intracranial volume (ICV). As many of the genetic

variants were known to be associated with MDD, we also adjusted for lifetime MDD status in sensitivity analyses. The final model was the following:

$$HSF \sim SNP + age + sex + batch + PC_{1-3} + education + ICV + (MDD)$$

where *HSF* denotes the hippocampal subfield volumes and *SNP* the genetic variants tested.

4.4.2. Interaction Analyses between Significant Genetic Factors from Section 4.4.1

For the significant genetic factors in Section 4.4.1, we additionally performed interaction analyses with the respective hippocampal structure as the outcome to assess a possible moderation effect. GWAS SNPs were included in the models if they could be replicated in TREND-0 for the respective hippocampal subfield. The model was the same as in Section 4.4.1, except that it included two genetic components and their interaction term:

$$HSF \sim SNP_1 \times SNP_2 + age + sex + batch + PC_{1-3} + education + ICV + (MDD)$$

where *HSF* denotes the hippocampal subfield volumes and *SNP* the genetic variants tested.

4.4.3. Association between Memory Performance and Hippocampal Subfields

OLS linear regression analyses with robust estimates were performed to assess the association between verbal memory scores (NAI) and hippocampal subfield volumes. Analyses were performed for immediate and delayed verbal memory scores, respectively, and adjusted for age, sex, ICV, education, and current depressive symptoms, as these are highly correlated with current memory performance [15]. As age-related effects on hippocampal volume loss and associated memory impairments are common, we additionally tested the effects of advanced age by splitting the sample into young versus old subjects (median split at age > 50 years) [85]. The final model was the following:

$$HSF \sim NAI + age + sex + education + ICV + PHQ-9$$

where *HSF* denotes the hippocampal subfield volumes and *NAI* the scores of the Nuremberg Age Inventory.

All reported *p*-values are two-sided. In all analyses, age was treated non-linearly as cubic splines with four knots. For all genetic variants, linear effects on hippocampal subfield volumes were assumed. As this was an exploratory approach aiming to replicate or disprove previous findings, the significance level was set to $p = 0.05$. All reported analyses were performed with STATA (v. 14.2) [86].

Supplementary Materials: The following supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/ijms24021120/s1>.

Author Contributions: Conceptualization, K.K.; data curation, K.W., S.A., R.B., H.M.z.S. and S.V.d.A.; formal analysis, S.V.d.A., L.G. and K.W.; funding acquisition, H.V. and S.V.d.A.; investigation, K.K. and S.A.; methodology, S.V.d.A.; project administration, S.V.d.A.; resources, H.V., R.B., M.N. and H.J.G.; supervision, H.J.G. and S.V.d.A.; visualization, S.A. and S.V.d.A.; writing—original draft, K.K. and S.V.d.A.; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

Funding: SHIP is part of the Community Medicine Research net of the University Medicine Greifswald, Germany, which is supported by the German Federal State of Mecklenburg-West Pomerania. This project was supported by the Federal Ministry of Education and Research (BMBF, gr. No. 01KU2004) under the frame of ERA PerMed (TRAJECTOME project, ERAPERMED2019-108). L.G. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—grant no. 403694598 and GR 1912/13-1. Genome-wide SNP typing in SHIP has been supported by a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg-West Pomerania.

Institutional Review Board Statement: The investigations in both studies were carried out in accordance with the Declaration of Helsinki. Survey and study methods were approved by the Ethics Committee at the University Medicine Greifswald, Germany.

Informed Consent Statement: Written informed consent was obtained from all participants involved in the study.

Data Availability Statement: Research data are available after formal application to the SHIP review board (https://www.fvcm.med.uni-greifswald.de/cm_antrag/index.php, accessed on 20 May 2022).

Conflicts of Interest: H.J.G. has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag, as well as research funding from Fresenius Medical Care. All other authors have no conflict to declare.

References

- Vilor-Tejedor, N.; Evans, T.E.; Adams, H.H.; González-de-Echávarri, J.M.; Molinuevo, J.L.; Guigo, R.; Gispert, J.D.; Operto, G. Genetic Influences on Hippocampal Subfields: An Emerging Area of Neuroscience Research. *Neurol. Genet.* **2021**, *7*, e591. [CrossRef] [PubMed]
- Hibar, D.P.; Adams, H.H.H.; Jahanshad, N.; Chauhan, G.; Stein, J.L.; Hofer, E.; Renteria, M.E.; Bis, J.C.; Arias-Vasquez, A.; Ikram, K.M.; et al. Novel genetic loci associated with hippocampal volume. *Nat. Commun.* **2017**, *8*, 13624. [CrossRef]
- Malhi, G.S.; Das, P.; Outhred, T.; Irwin, L.; Gessler, D.; Bwabi, Z.; Bryant, R.; Mannie, Z. The effects of childhood trauma on adolescent hippocampal subfields. *Aust. N. Z. J. Psychiatry* **2019**, *53*, 447–457. [CrossRef] [PubMed]
- Zammit, A.R.; Ezzati, A.; Zimmerman, M.E.; Lipton, R.B.; Lipton, M.L.; Katz, M.J. Roles of hippocampal subfields in verbal and visual episodic memory. *Behav. Brain Res.* **2017**, *317*, 157–162. [CrossRef] [PubMed]
- Genon, S.; Bernhardt, B.C.; La Joie, R.; Amunts, K.; Eickhoff, S.B. The many dimensions of human hippocampal organization and (dys)function. *Trends Neurosci.* **2021**, *44*, 977–989. [CrossRef]
- Shi, F.; Liu, B.; Zhou, Y.; Yu, C.; Jiang, T. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: Meta-analyses of MRI studies. *Hippocampus* **2009**, *19*, 1055–1064. [CrossRef]
- Li, J.-Q.; Tan, L.; Wang, H.-F.; Tan, M.-S.; Tan, L.; Xu, W.; Zhao, Q.-F.; Wang, J.; Jiang, T.; Yu, J.-T. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: A systematic review and meta-analysis of cohort studies. *J. Neurol. Neurosurg. Psychiatry* **2016**, *87*, 476–484. [CrossRef]
- Feng, F.; Huang, W.; Meng, Q.; Hao, W.; Yao, H.; Zhou, B.; Guo, Y.; Zhao, C.; An, N.; Wang, L.; et al. Altered Volume and Structural Connectivity of the Hippocampus in Alzheimer's Disease and Amnesic Mild Cognitive Impairment. *Front. Aging Neurosci.* **2021**, *13*, 705030. [CrossRef]
- Izzo, J.; Andreassen, O.A.; Westlye, L.T.; Van der Meer, D. The association between hippocampal subfield volumes in mild cognitive impairment and conversion to Alzheimer's disease. *Brain Res.* **2020**, *1728*, 146591. [CrossRef]
- Nobis, L.; Manohar, S.G.; Smith, S.M.; Alfaro-Almagro, F.; Jenkinson, M.; Mackay, C.E.; Husain, M. Hippocampal volume across age: Nomograms derived from over 19,700 people in UK Biobank. *Neuroimage Clin.* **2019**, *23*, 101904. [CrossRef]
- Van der Meer, D.; Rokicki, J.; Kaufmann, T.; Córdova-Palomera, A.; Moberget, T.; Alnæs, D.; Bettella, F.; Frei, O.; Doan, N.T.; Sørderby, I.E.; et al. Brain scans from 21,297 individuals reveal the genetic architecture of hippocampal subfield volumes. *Mol. Psychiatry* **2020**, *25*, 3053–3065. [CrossRef]
- El Haj, M.; Antoine, P.; Amouyel, P.; Lambert, J.-C.; Pasquier, F.; Kapogiannis, D. Apolipoprotein E (APOE) ϵ 4 and episodic memory decline in Alzheimer's disease: A review. *Ageing Res. Rev.* **2016**, *27*, 15–22. [CrossRef] [PubMed]
- Zhang, J.; Lin, L.; Dai, X.; Xiao, N.; Ye, Q.; Chen, X. ApoE4 increases susceptibility to stress-induced age-dependent depression-like behavior and cognitive impairment. *J. Psychiatr. Res.* **2021**, *143*, 292–301. [CrossRef] [PubMed]
- Vervoodt, S.M.; Arnett, P.; Engeland, C.; Rabinowitz, A.R.; Hillary, F.G. Depression associated with APOE status and hippocampal volume but not cognitive decline in older adults aging with traumatic brain injury. *Neuropsychology* **2021**, *35*, 863–875. [CrossRef]
- Bonk, S.; Kirchner, K.; Ameling, S.; Garvert, L.; Völzke, H.; Nauck, M.; Völker, U.; Grabe, H.J.; Van der Auwera, S. APOE ϵ 4 in Depression-Associated Memory Impairment-Evidence from Genetic and MicroRNA Analyses. *Biomedicines* **2022**, *10*, 1560. [CrossRef] [PubMed]
- Vilor-Tejedor, N.; Operto, G.; Evans, T.E.; Falcon, C.; Crous-Bou, M.; Minguillón, C.; Cacciaglia, R.; Milà-Alomà, M.; Grau-Rivera, O.; Suárez-Calvet, M.; et al. Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE- ϵ 4 in middle-age cognitively unimpaired individuals from the ALFA study. *Brain Struct. Funct.* **2020**, *225*, 2331–2345. [CrossRef]
- Stonnington, C.M.; Velgos, S.N.; Chen, Y.; Syed, S.; Huentelman, M.; Thiyyagura, P.; Lee, W.; Richholt, R.; Caselli, R.J.; Locke, D.E.; et al. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline. *JAD* **2020**, *78*, 721–734. [CrossRef] [PubMed]
- Molendijk, M.L.; van Tol, M.-J.; Penninx, B.W.J.H.; van der Wee, N.J.A.; Aleman, A.; Veltman, D.J.; Spinhoven, P.; Elzinga, B.M. BDNF val66met affects hippocampal volume and emotion-related hippocampal memory activity. *Transl. Psychiatry* **2012**, *2*, e74. [CrossRef]

19. Harrisberger, F.; Spalek, K.; Smieskova, R.; Schmidt, A.; Coynel, D.; Milnik, A.; Fastenrath, M.; Freytag, V.; Gschwind, L.; Walter, A.; et al. The association of the BDNF Val66Met polymorphism and the hippocampal volumes in healthy humans: A joint meta-analysis of published and new data. *Neurosci. Biobehav. Rev.* **2014**, *42*, 267–278. [\[CrossRef\]](#)
20. Li, X.; Tian, P.; Hu, X. Association of Met/Val polymorphism of BDNF gene with Alzheimer's disease in Chinese patients. *Cell. Mol. Biol.* **2022**, *68*, 46–51. [\[CrossRef\]](#)
21. Ferreira Fratelli, C.; Willatan Siqueira, J.; Rodrigues Gontijo, B.; de Lima Santos, M.; de Souza Silva, C.M.; Da Rodrigues Silva, I.C. BDNF Genetic Variant and Its Genotypic Fluctuation in Major Depressive Disorder. *Behav. Neurol.* **2021**, *2021*, 7117613. [\[CrossRef\]](#)
22. Toro, R.; Chupin, M.; Garnerio, L.; Leonard, G.; Perron, M.; Pike, B.; Pitiot, A.; Richer, L.; Veillette, S.; Pausova, Z.; et al. Brain volumes and Val66Met polymorphism of the BDNF gene: Local or global effects? *Brain Struct. Funct.* **2009**, *213*, 501–509. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Harrisberger, F.; Smieskova, R.; Schmidt, A.; Lenz, C.; Walter, A.; Wittfeld, K.; Grabe, H.J.; Lang, U.E.; Fusar-Poli, P.; Borgwardt, S. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: A systematic review and meta-analysis. *Neurosci. Biobehav. Rev.* **2015**, *55*, 107–118. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Papassotiropoulos, A.; Stephan, D.A.; Huentelman, M.J.; Hoernndli, F.J.; Craig, D.W.; Pearson, J.V.; Huynh, K.-D.; Brunner, F.; Corneveaux, J.; Osborne, D.; et al. Common Kibra alleles are associated with human memory performance. *Science* **2006**, *314*, 475–478. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Vogt-Eisele, A.; Krüger, C.; Duning, K.; Weber, D.; Spoelgen, R.; Pitzer, C.; Plaas, C.; Eisenhardt, G.; Meyer, A.; Vogt, G.; et al. KIBRA (KIdney/BRAin protein) regulates learning and memory and stabilizes Protein kinase M ϵ . *J. Neurochem.* **2014**, *128*, 686–700. [\[CrossRef\]](#)
26. Song, L.; Tang, S.; Dong, L.; Han, X.; Cong, L.; Dong, J.; Han, X.; Zhang, Q.; Wang, Y.; Du, Y. The Neuroprotection of KIBRA in Promoting Neuron Survival and Against Amyloid β -Induced Apoptosis. *Front. Cell. Neurosci.* **2019**, *13*, 137. [\[CrossRef\]](#)
27. Liu, J.J.; Lavebratt, C.; Lou, F.; Forsell, Y. KIBRA genetic polymorphism and cognitive dysfunction in depression. *Psychiatry Res.* **2015**, *226*, 405–406. [\[CrossRef\]](#) [\[PubMed\]](#)
28. Kauppi, K.; Nilsson, L.-G.; Adolfsson, R.; Eriksson, E.; Nyberg, L. KIBRA polymorphism is related to enhanced memory and elevated hippocampal processing. *J. Neurosci.* **2011**, *31*, 14218–14222. [\[CrossRef\]](#)
29. Palombo, D.J.; Amaral, R.S.C.; Olsen, R.K.; Müller, D.J.; Todd, R.M.; Anderson, A.K.; Levine, B. KIBRA polymorphism is associated with individual differences in hippocampal subregions: Evidence from anatomical segmentation using high-resolution MRI. *J. Neurosci.* **2013**, *33*, 13088–13093. [\[CrossRef\]](#)
30. Witte, A.V.; Köbe, T.; Kerti, L.; Rujescu, D.; Flöel, A. Impact of KIBRA Polymorphism on Memory Function and the Hippocampus in Older Adults. *Neuropsychopharmacology* **2016**, *41*, 781–790. [\[CrossRef\]](#)
31. Wang, J.; Wu, S.; Sun, Y.; Fang, Y.; Wu, R.; Lu, J.; Qing, Z.; Liang, X.; Wang, Z.; Zhang, W.; et al. Interaction of COMT and KIBRA modulates the association between hippocampal structure and episodic memory performance in healthy young adults. *Behav. Brain Res.* **2020**, *384*, 112550. [\[CrossRef\]](#) [\[PubMed\]](#)
32. Hayes, J.P.; Logue, M.W.; Reagan, A.; Salat, D.; Wolf, E.J.; Sadeh, N.; Spielberg, J.M.; Sperbeck, E.; Hayes, S.M.; McGlinchey, R.E.; et al. COMT Val158Met polymorphism moderates the association between PTSD symptom severity and hippocampal volume. *J. Psychiatry Neurosci.* **2017**, *42*, 95–102. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Otsuka, Y.; Kakeda, S.; Sugimoto, K.; Katsuki, A.; Le Nguyen, H.; Igata, R.; Watanabe, K.; Ueda, I.; Kishi, T.; Iwata, N.; et al. COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naïve patients with major depressive disorder. *Neuropsychiatr. Dis. Treat.* **2019**, *15*, 1537–1545. [\[CrossRef\]](#)
34. Porter, T.; Burnham, S.C.; Milicic, L.; Savage, G.; Maruff, P.; Sohrabi, H.R.; Peretti, M.; Lim, Y.Y.; Weinborn, M.; Ames, D.; et al. COMT val158met is not associated with A β -amyloid and APOE ϵ 4 related cognitive decline in cognitively normal older adults. *IBRO Rep.* **2019**, *6*, 147–152. [\[CrossRef\]](#)
35. Haefel, G.J.; Eastman, M.; Grigorenko, E.L. Using a cognitive endophenotype to identify risk genes for depression. *Neurosci. Lett.* **2012**, *510*, 10–13. [\[CrossRef\]](#)
36. Taylor, W.D.; Züchner, S.; Payne, M.E.; Messer, D.F.; Doty, T.J.; MacFall, J.R.; Beyer, J.L.; Krishnan, K.R.R. The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults. *Psychiatry Res.* **2007**, *155*, 173–177. [\[CrossRef\]](#)
37. Cerasa, A.; Gioia, M.C.; Labate, A.; Liguori, M.; Lanza, P.; Quattrone, A. Impact of catechol-O-methyltransferase Val(108/158) Met genotype on hippocampal and prefrontal gray matter volume. *Neuroreport* **2008**, *19*, 405–408. [\[CrossRef\]](#)
38. Honea, R.; Verchinski, B.A.; Pezawas, L.; Kolachana, B.S.; Callicott, J.H.; Mattay, V.S.; Weinberger, D.R.; Meyer-Lindenberg, A. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. *Neuroimage* **2009**, *45*, 44–51. [\[CrossRef\]](#) [\[PubMed\]](#)
39. Border, R.; Johnson, E.C.; Evans, L.M.; Smolen, A.; Berley, N.; Sullivan, P.F.; Keller, M.C. No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples. *Am. J. Psychiatry* **2019**, *176*, 376–387. [\[CrossRef\]](#)
40. Eker, M.C.; Kitis, O.; Okur, H.; Eker, O.D.; Ozan, E.; Isikli, S.; Akarsu, N.; Gonul, A.S. Smaller hippocampus volume is associated with short variant of 5-HTTLPR polymorphism in medication-free major depressive disorder patients. *Neuropsychobiology* **2011**, *63*, 22–28. [\[CrossRef\]](#)

41. Frodl, T.; Koutsouleris, N.; Bottlender, R.; Born, C.; Jäger, M.; Mörgenthaler, M.; Scheuerecker, J.; Zill, P.; Baghai, T.; Schüle, C.; et al. Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. *Mol. Psychiatry* **2008**, *13*, 1093–1101. [\[CrossRef\]](#)
42. Rabl, U.; Meyer, B.M.; Diers, K.; Bartova, L.; Berger, A.; Mandorfer, D.; Popovic, A.; Scharinger, C.; Huemer, J.; Kalcher, K.; et al. Additive gene-environment effects on hippocampal structure in healthy humans. *J. Neurosci.* **2014**, *34*, 9917–9926. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Little, K.; Olsson, C.A.; Whittle, S.; Youssef, G.J.; Byrne, M.L.; Simmons, J.G.; Yücel, M.; Foley, D.L.; Allen, N.B. Association between serotonin transporter genotype, brain structure and adolescent-onset major depressive disorder: A longitudinal prospective study. *Transl. Psychiatry* **2014**, *4*, e445. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Phillips, J.L.; Batten, L.A.; Tremblay, P.; Aldosary, F.; Du, L.; Blier, P. Impact of monoamine-related gene polymorphisms on hippocampal volume in treatment-resistant depression. *Acta Neuropsychiatr.* **2015**, *27*, 353–361. [\[CrossRef\]](#)
45. Ahdidan, J.; Foldager, L.; Rosenberg, R.; Rodell, A.; Videbech, P.; Mors, O. Hippocampal volume and serotonin transporter polymorphism in major depressive disorder. *Acta Neuropsychiatr.* **2013**, *25*, 206–214. [\[CrossRef\]](#)
46. Zhang, J.; Xu, D.; Cui, H.; Zhao, T.; Chu, C.; Wang, J. Group-guided individual functional parcellation of the hippocampus and application to normal aging. *Hum. Brain Mapp.* **2021**, *42*, 5973–5984. [\[CrossRef\]](#) [\[PubMed\]](#)
47. Tzioras, M.; Davies, C.; Newman, A.; Jackson, R.; Spires-Jones, T. Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease. *Neuropathol. Appl. Neurobiol.* **2019**, *45*, 327–346. [\[CrossRef\]](#) [\[PubMed\]](#)
48. Tsai, S.-J. Critical Issues in BDNF Val66Met Genetic Studies of Neuropsychiatric Disorders. *Front. Mol. Neurosci.* **2018**, *11*, 156. [\[CrossRef\]](#)
49. Popova, N.K.; Naumenko, V.S. Neuronal and behavioral plasticity: The role of serotonin and BDNF systems tandem. *Expert Opin. Ther. Targets* **2019**, *23*, 227–239. [\[CrossRef\]](#)
50. Weerasinghe-Mudiyanselage, P.D.E.; Ang, M.J.; Kang, S.; Kim, J.-S.; Moon, C. Structural Plasticity of the Hippocampus in Neurodegenerative Diseases. *Int. J. Mol. Sci.* **2022**, *23*, 3349. [\[CrossRef\]](#)
51. Stepan, J.; Dine, J.; Eder, M. Functional optical probing of the hippocampal trisynaptic circuit in vitro: Network dynamics, filter properties, and polysynaptic induction of CA1 LTP. *Front. Neurosci.* **2015**, *9*, 160. [\[CrossRef\]](#) [\[PubMed\]](#)
52. Lazarov, O.; Hollands, C. Hippocampal neurogenesis: Learning to remember. *Prog. Neurobiol.* **2016**, *138–140*, 1–18. [\[CrossRef\]](#)
53. Tahami Monfared, A.A.; Byrnes, M.J.; White, L.A.; Zhang, Q. Alzheimer's Disease: Epidemiology and Clinical Progression. *Neurol. Ther.* **2022**, *11*, 553–569. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Kaye, R.; Lasagna-Reeves, C.A. Molecular Mechanisms of Amyloid Oligomers Toxicity. *J. Alzheimer's Dis.* **2013**, *33* (Suppl. 1), 67–78. [\[CrossRef\]](#)
55. Sengupta, U.; Nilson, A.N.; Kaye, R. The Role of Amyloid- β Oligomers in Toxicity, Propagation, and Immunotherapy. *EBioMedicine* **2016**, *6*, 42–49. [\[CrossRef\]](#)
56. Grabe, H.J.; Schwahn, C.; Mahler, J.; Appel, K.; Schulz, A.; Spitzer, C.; Fenske, K.; Barnow, S.; Freyberger, H.J.; Teumer, A.; et al. Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorphism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2012**, *36*, 264–270. [\[CrossRef\]](#)
57. Li, S.; Weinstein, G.; Zare, H.; Teumer, A.; Völker, U.; Friedrich, N.; Knol, M.J.; Satizabal, C.L.; Petyuk, V.A.; Adams, H.H.H.; et al. The genetics of circulating BDNF: Towards understanding the role of BDNF in brain structure and function in middle and old ages. *Brain Commun.* **2020**, *2*, fcaa176. [\[CrossRef\]](#) [\[PubMed\]](#)
58. Teng, H.K.; Teng, K.K.; Lee, R.; Wright, S.; Tevar, S.; Almeida, R.D.; Kermani, P.; Torkin, R.; Chen, Z.-Y.; Lee, F.S.; et al. proBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. *J. Neurosci.* **2005**, *25*, 5455–5463. [\[CrossRef\]](#)
59. Fleitas, C.; Piñol-Ripoll, G.; Marfull, P.; Rocandio, D.; Ferrer, I.; Rampon, C.; Egea, J.; Espinet, C. proBDNF is modified by advanced glycation end products in Alzheimer's disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processing. *Mol. Brain* **2018**, *11*, 68. [\[CrossRef\]](#) [\[PubMed\]](#)
60. Yang, B.; Wang, L.; Nie, Y.; Wei, W.; Xiong, W. proBDNF expression induces apoptosis and inhibits synaptic regeneration by regulating the RhoA-JNK pathway in an in vitro post-stroke depression model. *Transl. Psychiatry* **2021**, *11*, 578. [\[CrossRef\]](#)
61. Smith, G.S.; Barret, F.S.; Joo, J.H.; Nassery, N.; Savonenko, A.; Sodums, D.J.; Marano, C.M.; Munro, C.A.; Brandt, J.; Kraut, M.A.; et al. Molecular imaging of serotonin degeneration in mild cognitive impairment. *Neurobiol. Dis.* **2017**, *105*, 33–41. [\[CrossRef\]](#)
62. Mattson, M.P.; Maudsley, S.; Martin, B. BDNF and 5-HT: A dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. *Trends Neurosci.* **2004**, *27*, 589–594. [\[CrossRef\]](#)
63. Haase, J.; Brown, E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression—a central role for the serotonin transporter? *Pharmacol. Ther.* **2015**, *147*, 1–11. [\[CrossRef\]](#)
64. Levy, M.J.F.; Boule, F.; Steinbusch, H.W.; van den Hove, D.L.A.; Kenis, G.; Lanfumey, L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. *Psychopharmacology* **2018**, *235*, 2195–2220. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Porcelli, S.; Fabbri, C.; Serretti, A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. *Eur. Neuropsychopharmacol.* **2012**, *22*, 239–258. [\[CrossRef\]](#) [\[PubMed\]](#)

66. Schoenfeld, E.M.; Gupta, N.K.; Syed, S.A.; Rozenboym, A.V.; Fulton, S.L.; Jackowski, A.P.; Perera, T.D.; Coplan, J.D. Developmental Antecedents of Adult Macaque Neurogenesis: Early-Life Adversity, 5-HTTLPR Polymorphisms, and Adolescent Hippocampal Volume. *J. Affect. Disord.* **2021**, *286*, 204–212. [[CrossRef](#)] [[PubMed](#)]
67. Lee, E.; Kwak, G.-H.; Kamble, K.; Kim, H.-Y. Methionine sulfoxide reductase B3 deficiency inhibits cell growth through the activation of p53-p21 and p27 pathways. *Arch. Biochem. Biophys.* **2014**, *547*, 1–5. [[CrossRef](#)]
68. Adams, S.L.; Benayoun, L.; Tilton, K.; Chavez, O.R.; Himali, J.J.; Blusztajn, J.K.; Seshadri, S.; Delalle, I. Methionine Sulfoxide Reductase-B3 (MsrB3) Protein Associates with Synaptic Vesicles and its Expression Changes in the Hippocampi of Alzheimer's Disease Patients. *JAD* **2017**, *60*, 43–56. [[CrossRef](#)]
69. Zheng, T.; Ge, B.; Qin, L.; Chen, B.; Tian, L.; Gao, Y.; Xiao, L.; Hu, X.; Pan, H.; Chen, Y. Association of Plasma DPP4 Activity and Brain-Derived Neurotrophic Factor With Moderate to Severe Depressive Symptoms in Patients With Type 2 Diabetes: Results From a Cross-Sectional Study. *Psychosom. Med.* **2020**, *82*, 350–358. [[CrossRef](#)]
70. Behesti, H.; Fore, T.R.; Wu, P.; Horn, Z.; Leppert, M.; Hull, C.; Hatten, M.E. ASTN2 modulates synaptic strength by trafficking and degradation of surface proteins. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E9717–E9726. [[CrossRef](#)]
71. Bauleo, A.; Montesanto, A.; Pace, V.; Brando, R.; de Stefano, L.; Puntorieri, D.; Cento, L.; Loddo, S.; Calacci, C.; Novelli, A.; et al. Rare copy number variants in ASTN2 gene in patients with neurodevelopmental disorders. *Psychiatr. Genet.* **2021**, *31*, 239–245. [[CrossRef](#)] [[PubMed](#)]
72. Völzke, H.; Schöswow, J.; Schmidt, C.O.; Jürgens, C.; Richter, A.; Werner, A.; Werner, N.; Radke, D.; Teumer, A.; Ittermann, T.; et al. Cohort Profile Update: The Study of Health in Pomerania (SHIP). *Int. J. Epidemiol.* **2022**, *51*, e372–e383. [[CrossRef](#)] [[PubMed](#)]
73. Oswald, W.D.; Fleischmann, U.M. (Eds.) Nürnberger-Alters-Inventar: (NAI). In *NAI-Testmanual und Textband*; Hogrefe: Boston, MA, USA, 1999.
74. Van der Auwera, S.; Terock, J.; Teumer, A.; Schomerus, G.; Homuth, G.; Grabe, H.J. Sex effects for the interaction of dopamine related genetic variants for COMT and BDNF on declarative memory performance. *Genes Brain Behav.* **2021**, *20*, e12737. [[CrossRef](#)]
75. Wittchen, H.U. Reliability and Validity Studies of the WHO-Composite International Diagnostic Interview (CIDI: A Critical Review. *J. Psychiatr. Res.* **1994**, *28*, 57–84. [[CrossRef](#)]
76. Wittchen, H.U.; Lachner, G.; Wunderlich, U.; Pfister, H. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). *Soc. Psychiatry Psychiatr. Epidemiol.* **1998**, *33*, 568–578. [[CrossRef](#)]
77. Kroenke, K.; Spitzer, R.L.; Williams, J.W. The PHQ-9: Validity of a Brief Depression Severity Measure. *J. Gen. Intern. Med.* **2001**, *16*, 606–613. [[CrossRef](#)] [[PubMed](#)]
78. Habes, M.; Toledo, J.B.; Resnick, S.M.; Doshi, J.; van der Auwera, S.; Erus, G.; Janowitz, D.; Hegenscheid, K.; Homuth, G.; Völzke, H.; et al. Relationship between APOE Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort. *AJNR. Am. J. Neuroradiol.* **2016**, *37*, 1636–1642. [[CrossRef](#)]
79. Ge, T.; Chen, C.-Y.; Ni, Y.; Feng, Y.-C.A.; Smoller, J.W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **2019**, *10*, 1776. [[CrossRef](#)]
80. Kunkle, B.W.; Grenier-Boley, B.; Sims, R.; Bis, J.C.; Damotte, V.; Naj, A.C.; Boland, A.; Vronskaya, M.; van der Lee, S.J.; Amlie-Wolf, A.; et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat. Genet.* **2019**, *51*, 414–430. [[CrossRef](#)]
81. Bycroft, C.; Freeman, C.; Petkova, D.; Band, G.; Elliott, L.T.; Sharp, K.; Motyer, A.; Vukcevic, D.; Delaneau, O.; O'Connell, J.; et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **2018**, *562*, 203–209. [[CrossRef](#)]
82. Grabe, H.J.; Wittfeld, K.; Hegenscheid, K.; Hosten, N.; Lotze, M.; Janowitz, D.; Völzke, H.; John, U.; Barnow, S.; Freyberger, H.J. Alexithymia and brain gray matter volumes in a general population sample. *Hum. Brain Mapp.* **2014**, *35*, 5932–5945. [[CrossRef](#)] [[PubMed](#)]
83. Hosten, N.; Bülow, R.; Völzke, H.; Domin, M.; Schmidt, C.O.; Teumer, A.; Ittermann, T.; Nauck, M.; Felix, S.B.; Dörr, M.; et al. SHIP-MR and Radiology: 12 Years of Whole-Body Magnetic Resonance Imaging in a Single Center. *Healthcare* **2022**, *10*, 33. [[CrossRef](#)] [[PubMed](#)]
84. Iglesias, J.E.; Augustinack, J.C.; Nguyen, K.; Player, C.M.; Player, A.; Wright, M.; Roy, N.; Frosch, M.P.; McKee, A.C.; Wald, L.L.; et al. A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI. *Neuroimage* **2015**, *115*, 117–137. [[CrossRef](#)] [[PubMed](#)]
85. von Bohlen und Halbach, O. Involvement of BDNF in age-dependent alterations in the hippocampus. *Front. Aging Neurosci.* **2010**, *2*, 36. [[CrossRef](#)]
86. StataCorp LLC. *STATA 14*; StataCorp: College Station, TX, USA, 2016.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.